FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Geoffrey Kim1, Gwynn Ison1, Amy E. McKee1, Hui Zhang2, Shenghui Tang2, Thomas Gwise2, Rajeshwari Sridhara2, Eunice Lee3, Abraham Tzou3, Reena Philip3, Haw-Jyh Chiu1, Tiffany K. Ricks1, Todd Palmby1, Anne Marie Russell1, Gaetan Ladouceur4, Elimika Pfuma5, Hongshan Li5, Liang Zhao5, Qi Liu5, Rajesh Venugopal1, Amna Ibrahim1, and Richard Pazdur1

Abstract

On December 19, 2014, the FDA approved olaparib capsules (Lynparza; AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. The BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.) was approved concurrently. An international multicenter, single-arm trial enrolled 137 patients with measurable gBRCAm-associated ovarian cancer treated with three or more prior lines of chemotherapy. Patients received olaparib at a dose of 400 mg by mouth twice daily until disease progression or unacceptable toxicity. The objective response rate (ORR) was 34% with median response duration of 7.9 months in this cohort. The most common adverse reactions (≥20%) in patients treated with olaparib were anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis/upper respiratory infection, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash, and abdominal pain/discomfort. Myelodysplastic syndrome and/or acute myeloid leukemia occurred in 2% of the patients enrolled on this trial.

Introduction

Therapy for relapsed ovarian cancer is dependent on the interval between the date of the final dose of initial therapy and date of relapse, with platinum-sensitive ovarian cancer being defined as relapse that occurs more than 6 months from the date of the last dose of platinum-based chemotherapy (1). Multiple options exist for relapsed ovarian cancer; however, data are limited on the response rates for therapy in the fourth-line setting regardless of platinum sensitivity. Several institutions have described their experience with third-line chemotherapy regimens, and the response rates ranged from 5% to 40% (2–5). There are no agents specifically approved in this disease setting.

The BRCA genes BRCA1 and BRCA2 encode proteins involved in the DNA damage repair pathway. Deleterious mutations of BRCA1 and BRCA2 are associated with an increased risk of the development of breast and ovarian cancers; however, not all mutations are considered to be deleterious (6, 7). The majority of deleterious mutations are protein-truncating mutations. Missense mutations and large rearrangements of DNA segments within the BRCA genes also result in loss of function. It is estimated that the incidence of deleterious germline BRCA mutation (gBRCAm)-associated ovarian cancer is approximately 10% to 15% of all cases of ovarian cancer, corresponding to an annual incidence of approximately 2,000 cases per year in the United States (8, 9).

Patients with gBRCAm-associated ovarian cancer are treated no differently than patients without a deleterious mutation, but the presence of a mutation appears to be positively correlated with increased survival and responsiveness to chemotherapy (10–12). Because of the increased susceptibility to chemotherapy, it is expected that the patient with gBRCAm-associated ovarian cancer will be exposed to multiple lines of chemotherapy, and cumulative toxicity is a key concern in heavily pretreated patients.

Chemistry

Olaparib is an inhibitor of the mammalian PARP enzyme. Its chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)
with baseline serum bilirubin with CLcr less than 30 mL/min, patients on dialysis, or patients on the exposure of olaparib. Data are not available in patients with CLcr less than 30 mL/min or higher, creatinine clearance (CLcr) had no influence. At the level of tumor growth in mouse xenograft models of human cancer. Increased cytotoxicity and antitumor activity following treatment with olaparib were noted in vitro and in mouse tumor models with cell lines deficient in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of the PARP–DNA complex, resulting in disruption of cellular homeostasis and cell death (13).

Repeat-dose toxicity studies evaluated the effects of daily doses of oral olaparib in rats and dogs for up to 26 weeks. The major target organ was the hematopoietic system, with reduced red cell mass and leukopenia reported in rats and dogs at ≥2% and 4%, respectively, of the human AUC at the recommended clinical dose. Gastrointestinal toxicities (diarrhea, constipation, hemorrhage, and inflammation) were considered minimal in severity and noted in 4- and 26-week repeat-dose toxicity studies in dogs at ≥4% of the human AUC at the recommended clinical dose.

In early–fetal development studies, olaparib was embryotoxic and teratogenic when administered to pregnant rats during the period of organogenesis.

BRCA and PARP are key components of the DNA damage repair pathway. Specifically, both BRCA1 and BRCA2 proteins critically interact with Fanconi Anemia proteins in the homologous recombination pathway (14). Limited data exist regarding the increased risk for the development of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients with germline BRCA mutations; however, because of the interactions among BRCA1, BRCA2, and Fanconi Anemia proteins, BRCA deficiency may increase the risk for the development of MDS/AML (15). The addition of further DNA damage induced by chemotherapy or other environmental factors, coupled with further impairment of a compensatory repair pathway by means of PARP inhibition, may prime patients with germline DNA repair deficiencies for the development of MDS/AML.

Clinical Pharmacology

Following oral administration of olaparib, absorption is rapid, with peak plasma concentrations typically achieved between 1 and 3 hours after dosing. Steady-state exposures are achieved within 3 to 4 days. The mean half-life of olaparib is 12 hours at the 400-mg dose with an accumulation ratio of 1.4 with twice daily dosing. A high-fat meal did not increase the exposure of olaparib significantly; therefore, olaparib can be dosed without regard to food intake.

The results from the oral mass balance trial suggest that metabolism is an important elimination pathway for olaparib, but the contribution of the renal route cannot be ruled out. At the level of 30 mL/min or higher, creatinine clearance (CLcr) had no influence on the exposure of olaparib. Data are not available in patients with CLcr less than 30 mL/min, patients on dialysis, or patients with baseline serum bilirubin > 1.5 x ULN.

The maximum tolerated dose of olaparib was identified as 400 mg twice daily based on safety assessments in a phase 1 study. In other trials with olaparib, an exposure–response relationship was identified for anemia in the dose range of 100 to 400 mg twice daily showing an increased risk of anemia with increase in olaparib steady-state concentrations.

Olaparib is primarily metabolized by CYP3A. A strong CYP3A inhibitor increased the AUC of olaparib by 2.7-fold, and PBPK modeling predicted that a moderate CYP3A inhibitor would likely increase olaparib AUC by 2-fold. Dose reductions to 150 mg twice daily are recommended for concomitant use of a strong CYP3A inhibitor and to 200 mg for concomitant use of a moderate CYP3A inhibitor. A strong CYP3A inducer decreased the AUC of olaparib by 87%, and PBPK modeling predicted that a moderate CYP3A inducer would likely decrease olaparib AUC by half. Concomitant use of a strong or moderate CYP3A inducer should be avoided. If a moderate CYP3A inducer must be coadministered, there is a potential for reduced efficacy.

Clinical Trials

FDA approval of olaparib was primarily based on an open-label, nonrandomized clinical trial in 298 patients with deleterious or suspected deleterious gBRCAm-associated cancer, including 193 patients with ovarian cancer (16). Patients were treated with olaparib capsules at a dose of 400 mg orally twice daily until disease progression or intolerance to therapy. Local test results for BRCA status were used to assess patient eligibility for the trial. Samples from a subset of enrolled patients from the intended population were retrospectively evaluated at one laboratory, Myriad Genetic Laboratories, Inc., using the BRACAnalysis CDx in a clinical bridging study.

Of the 193 patients in the ovarian cancer cohort, 137 patients had measurable disease at baseline and had received three or more prior lines of chemotherapy. The majority (94%) of these patients were white/Caucasian and had a baseline ECOG performance status of 0 or 1 (93%); the median age at enrollment was 58 years. The median number of prior chemotherapies regimens was five, and the maximum number of prior regimens was 14.

Efficacy results

The primary endpoint was investigator-assessed tumor response rate by RECIST v.1.1 in all treated patients. Secondary objectives included objective response rate (ORR) in patients with measurable disease only and duration of response (DOR). A blinded independent radiologic review was not performed. The ORR was 34% [95% confidence interval (CI), 26–42] with a median DOR of 7.9 months (Table 1).

Of the 137 patients, specimens from 61 patients were available for retrospective testing with the BRACAnalysis CDx in the
bridging study for clinical validation of the device. The concordance between the local test results, as reported in the Case Report Form, and the results from the BRACAnalysis CDx were 96.7% (59/61; 95% CI, 88.7–99.6). Among the discordant results, one sample did not yield a callable result with the BRACAnalysis CDx, and another sample had different classification results between the local test and the BRACAnalysis CDx (deleterious vs. variant of unknown significance, respectively), although the specific variant that was detected by both tests matched. The ORR for the 59 patients with confirmed gBRCA mutations was 41% (95% CI, 28–54), with a median DOR of 8.0 months.

Safety results

The primary safety population included 223 patients from six studies, including patients with relapsed ovarian cancer with gBRCA mutation who had received three or more prior treatment regimens. The median exposure to olaparib in this population was 158 days. Dose interruptions were reported in 40% of these patients, and dose reductions were reported in 4%. Treatment discontinuations due to adverse drug reaction occurred in 7%. The most common adverse events leading to treatment discontinuation included nausea and vomiting, intestinal obstruction, anemia, and thrombocytopenia.

Eight patients (4%) had adverse reactions leading to death. The fatal adverse reactions included 2 patients with acute leukemia and 1 patient each with death attributed to chronic obstructive pulmonary disease, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture.

The most common (>20%) grade 1–4 adverse events in patients receiving olaparib are shown in Table 2. Thirty-five percent of patients experienced one or more serious adverse events, and the most common of these events are shown in Table 3.

Mycoplasma pneumoniae and acute leukemia are the most concerning adverse reactions associated with olaparib therapy. Six confirmed cases of MDS/AML occurred in the 298 patients (2%) enrolled in the single-arm study of olaparib monotherapy in patients with gBRCAm-associated ovarian cancer. In a randomized placebo controlled trial of olaparib maintenance monotherapy in platinum-sensitive ovarian cancer, MDS/AML occurred in 158 days. Dose interruptions were reported in 40% of these regimens. The median exposure to olaparib in this population was 17) and in patients who were currently being treated for ovarian cancer (n = 18). Of those patients with gBRCAm status, 6 patients with ovarian cancer had a prior history of breast cancer, and the 1 patient with breast cancer had a history of ovarian cancer. Further epidemiologic research is needed to understand the baseline risk of developing therapy-related MDS/AML in patients with gBRCAm status; however, given the mechanism of action and increased rates of MDS/AML seen in the randomized studies of olaparib, there exists a clear safety signal that olaparib may increase the risk of developing MDS/AML.

Table 2. Common adverse reactions in a pooled gBRCAm population

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Three or more lines of prior chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1–4 (N = 223)</td>
</tr>
<tr>
<td>Blood and lymphatic disorders</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>34</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>64</td>
</tr>
<tr>
<td>Abdominal pain/discomfort</td>
<td>43</td>
</tr>
<tr>
<td>Vomiting</td>
<td>43</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>31</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>25</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>22</td>
</tr>
<tr>
<td>General disorders</td>
<td></td>
</tr>
<tr>
<td>Fatigue/asthenia</td>
<td>66</td>
</tr>
<tr>
<td>Infectious and infestations</td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis/URI</td>
<td>26</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>22</td>
</tr>
<tr>
<td>Arthralgia/musculoskeletal pain</td>
<td>21</td>
</tr>
</tbody>
</table>

Abbreviation: URI, upper respiratory infection.

Table 3. Serious adverse reactions in a pooled gBRCAm population

<table>
<thead>
<tr>
<th>Serious adverse reaction</th>
<th>Three or more lines of prior chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1–4 (N = 223)</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>5</td>
</tr>
<tr>
<td>Neutropenia/febrile neutropenia/leukopenia</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Bowel obstruction</td>
<td>9</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>4</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td>Sepsis/infection</td>
<td>3</td>
</tr>
</tbody>
</table>

Of the 136 patients treated with olaparib (2%) as compared with 1 of the 129 patients treated with placebo (0.8%). Among the 2,618 patients exposed to olaparib at the time of the FDA review, 22 cases of MDS/AML were reported (0.8%), with 17 cases resulting in death. The precise number of patients with gBRCAm status who have been exposed to olaparib is unknown, but the majority of cases occurred in patients with gBRCAm status (n = 17) and in patients who were currently being treated for ovarian cancer (n = 18). Of those patients with gBRCAm status, 6 patients with ovarian cancer had a prior history of breast cancer, and the 1 patient with breast cancer had a history of ovarian cancer. Further epidemiologic research is needed to understand the baseline risk of developing therapy-related MDS/AML in patients with gBRCAm status; however, given the mechanism of action and increased rates of MDS/AML seen in the randomized studies of olaparib, there exists a clear safety signal that olaparib may increase the risk of developing MDS/AML.

Discussion

Olaparib is the first new molecular entity approved for the treatment of ovarian cancer since 1996. The long gap between approvals demonstrates the challenge of developing novel therapeutic options in ovarian cancer, as standard therapeutic regimens for the first-line and platinum-sensitive settings have high antitumor activity with benefits in overall survival, making it difficult to use an "add-on" trial design in which a new drug is added to an existing regimen. In more refractory ovarian cancer settings, randomized trials are possible, but a convincing demonstration of efficacy in a more resistant population has been elusive. Bevacizumab was recently approved as a supplemental Biologic License Application for use in combination with chemotherapy for the treatment of patients with platinum-resistant ovarian cancer based on the results of a randomized trial demonstrating an improvement in progression-free survival (PFS), which marked the first approval in this setting for over 15 years (17).

On June 25, 2014, New Drug Application 206162 was brought to the FDA’s Oncologic Drug Advisory Committee (ODAC) to discuss olaparib for the maintenance treatment of gBRCAm-associated ovarian cancer based on the results of Study 19, a randomized placebo controlled trial assessing PFS in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer in partial or complete response to their last platinum-containing regimen (18). The efficacy results were based primarily on the prespecified subgroup analysis of 96 patients with deleterious germline BRCA mutations who were mostly retrospectively...
identified (19). The committee was asked whether the efficacy results, namely a 7-month improvement in median PFS and an HR of 0.17, along with the safety data in the gBRCAm population, demonstrated a favorable risk–benefit profile of olaparib maintenance monotherapy in gBRCAm-associated ovarian cancer.

After a robust discussion, the committee voted 11–2 that the results from Study 19 do not support an accelerated approval for the proposed indication. Primary reasons for voting against approval included a lack of OS benefit for maintenance therapy; uninterruptable results due to lack of multiplicity adjustment; unreliable results due to loss of randomization and small sample size; toxicity of therapy and risk of MDS/AML for patients not otherwise undergoing treatment; and a potential to hinder accrual to the confirmatory study.

Following the ODAC meeting and in further discussion with the FDA, the applicant submitted additional information in support of the use of olaparib monotherapy in a more refractory and narrowly defined population of patients with gBRCAm-associated ovarian cancer treated with three or more lines of chemotherapy. The applicant has addressed the concerns raised by the ODAC, as the approved indication is not in a maintenance setting, and patients typically would be treated with chemotherapy at this time. Enrollment for a potential confirmatory trial discussed at ODAC, SOLO-2, is complete.

This approval is not restricted to either the platinum-sensitive or platinum-resistant disease setting. Many patients with gBRCAm-associated ovarian cancer may still be responsive to platinum-based therapy even after three prior lines of chemotherapy; however, it is estimated that treatment with olaparib would have a better response rate and favorable safety profile as compared with available single-agent chemotherapeutic options. Patients in this disease setting will most likely have cumulative toxicity and would benefit from a drug with demonstrable anti-tumor activity and a relatively mild safety profile. The tolerability profile of olaparib in this heavily pretreated population was an important factor in determining the overall benefit–risk assessment of olaparib therapy. The applicant is conducting a randomized trial (SOLO-3) directly comparing the safety and efficacy of olaparib monotherapy versus chemotherapy in the third-line ovarian cancer setting that also could be a potential confirmatory trial.

Overall, olaparib monotherapy represents a new treatment modality for patients with advanced, heavily pretreated gBRCAm-associated ovarian cancer; however, the clinical benefit must be confirmed in a randomized clinical trial. In addition, the risks of the development of MDS/AML must be further characterized, and this led to a post-marketing requirement (PMR) for annual reporting to the FDA of all cases of MDS/AML from ongoing clinical trials and spontaneous safety reports. Other PMRs included the assessment of olaparib in patients with renal impairment and with hepatic impairment.

Further information regarding the review of the application can be found at the Drugs@FDA website (20). Information about the device application can be found online at the FDA PMA database website (21).

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: G. Kim, G. Ison, A.E. McKee, R. Sridhara, R. Pazdur
Development of methodology: G. Kim, A.E. McKee, R. Sridhara, L. Zhao
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G. Kim, R. Venugopal
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): G. Kim, G. Ison, A.E. McKee, R. Venugopal
Study supervision: R. Sridhara, R. Pazdur
Other (supervised the review of the application): A. Ibrahim

Received April 13, 2015; revised June 1, 2015; accepted June 7, 2015; published OnlineFirst July 17, 2015.

References

4260 Clin Cancer Res; 21(19) October 1, 2015 Clinical Cancer Research
Clinical Cancer Research

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Geoffrey Kim, Gwynn Ison, Amy E. McKee, et al.


Updated version
Access the most recent version of this article at:

Cited articles
This article cites 19 articles, 7 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/19/4257.full.html#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/21/19/4257.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.